Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study.

Sponsor
Association de Recherche Bibliographique pour les Neurosciences (Other)
Overall Status
Completed
CT.gov ID
NCT05254873
Collaborator
Centre Hospitalier Princesse Grace (Other)
7
1
2.1
3.3

Study Details

Study Description

Brief Summary

EYE-TAR(MA)-Follow-Up is a non-interventionel, long-term follow-up study in subjects who participated to the study referred as EYE-TAR(MA) (NCT04730440)

EYE-TAR(MA)-Follow-Up aims to evaluate the long-term impacts of the Training of Affect Recognition TAR (an emotion recognition rehabilitation program), on social cognition abilities, evolve gaze strategies, behavioral disorders, and the caregiver's burden in Alzheimer's disease (AD).

Subjects who completed EYE-TAR(MA) study, and who have signed informed consent for this follow-up, will be eligible to enroll. They will attend one visit two years post EYE-TAR(MA) study intervention (intervention was TAR, or a "classic" cognitive stimulation program) to undergo the following evaluation: Eye-tracking recording during Ekman Faces task, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Zarit scale (completed by caregiver).

Condition or Disease Intervention/Treatment Phase
  • Other: Long term follow-up

Detailed Description

It is commonly admitted that social cognition impairment, like deficit in facial emotion recognition or misinterpretation of others' intentions (Theory of Mind), are associated with social behavior disorders.

This kind of disorders are observed in Fronto-Temporal Dementia (FTD), Alzheimer's Dementia (AD) and Parkinson's Disease (PD), with severe deficits in FTD and lighter deficits in AD and PD. One explanation is that patients apply inappropriate visual exploration strategies to decode emotions and intentions of others.

The study EYE-TAR(MA), NCT04730440, aimed to evaluate impacts of an emotion recognition rehabilitation program, named Training of Affect Recognition (TAR), on social cognition abilities (facial emotion recognition and theory of mind) in AD. In addition, investigators hypothesized that the effect of this rehabilitation will also evolve gaze strategies, behavioral disorders, and the caregiver's burden.

EYE-TAR(MA) results showed that participants who participated to the TAR (a) recognized facial emotions better and faster, especially sadness, fear and neutral expression; (b) evolved their gaze strategies on emotional faces with increased observation of the upper part of the face (nose and / or eyes); (c) had reduced behavioral disorders and the caregiver's burden. These results were specific to the TAR, since no significant change was observed in the AD-Control group who had participated in a "classic" cognitive stimulation program.

These changes were generally maintained one month after treatment.

Because there is not long-term follow-up data for these patients, Sponsor and investigators set-up the EYE-TAR(MA)-Follow-Up study to evaluate the long-term impacts of the Training of Affect Recognition, on social cognition abilities, evolve gaze strategies, behavioral disorders, and the caregiver's burden.

Subjects who completed EYE-TAR(MA) study, and who have signed informed consent for this follow-up, will be eligible to enroll. They will attend a visit two years post EYE-TAR(MA) study intervention to undergo the following evaluation: Eye-tracking recording during Ekman Faces task, Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI), Zarit scale (completed by caregiver).

Study Design

Study Type:
Observational
Actual Enrollment :
7 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Long-term Follow-up of Patients Included in the EYE-TAR(MA) Study: Rehabilitation of Facial Emotion Recognition in Alzheimer's Disease and Study of the Consequences on Gaze Strategy, Behavior Disorders and Family Caregivers' Burden
Actual Study Start Date :
Feb 5, 2022
Actual Primary Completion Date :
Apr 11, 2022
Actual Study Completion Date :
Apr 11, 2022

Arms and Interventions

Arm Intervention/Treatment
AD-TAR

AD subjects who took part to Facial Emotion Recognition rehabilitation (TAR) during EYE-TAR(MA) study

Other: Long term follow-up
Long term follow-up for patient who completed the EYE-TAR(MA) study.

AD-Cognitive Stim

AD subjects who took part to cognitive stimulation session (12 sessions during 4 weeks) during EYE-TAR(MA) study

Other: Long term follow-up
Long term follow-up for patient who completed the EYE-TAR(MA) study.

Outcome Measures

Primary Outcome Measures

  1. Facial emotion recognition (FER) performances [2 years follow-up]

    Change from EYE-TAR(MA) Last evaluation and Comparison of FER performance between Long-term follow-up AD-TAR group and Long-term follow-up AD-Cognitive Stimulation group. Evaluation criteria: Scores to Ekman Faces task (1976) and time to answer. FER was assessed using pictures from the Ekman Faces task (1976), to test the recognition of the six facial basic emotions and neutral faces. There were four pictures per emotion, for a total of 28. For each picture, participants were asked to select one of the seven labels (anger, disgust, fear, sadness, happiness, surprise and neutral), with a maximum of 8 seconds of response time per picture.

Secondary Outcome Measures

  1. Eye gaze strategies during Facial emotion recognition (FER) [2 years follow-up]

    Change from EYE-TAR(MA) Last evaluation and Comparison of gaze patterns between Long-term follow-up AD-TAR group and Long-term follow-up AD-Cognitive Stimulation group. Evaluation criteria: Eye movements (number and duration of fixations on areas of interest) recorded with an eye-tracking device. FER was assessed using some pictures from the Ekman Faces task (1976).

  2. Behavioral disorders [2 years follow-up]

    Change from EYE-TAR(MA) Last evaluation and Comparison between Long-term follow-up AD-TAR group and Long-term follow-up AD-Cognitive Stimulation group. Evaluation criteria: Neuropsychiatric Inventory (NPI), a scale that includes ten behavioral items (delusions, hallucinations, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability and aberrant motor behaviors) and two neurovegetative symptoms (sleep and appetite disorders). The evaluation was based on an interview with patients' primary caregivers. Both the frequency (/5) and the severity (/3) of each behavior were determined and a score was calculated by multiplying the frequency and the severity of each behavior observed during the last month.

  3. The Family caregiver's burden [2 years follow-up]

    Change from EYE-TAR(MA) Last evaluation and Comparison between Long-term follow-up AD-TAR group and Long-term follow-up AD-Cognitive Stimulation group. Evaluation criteria: The burden of the family caregiver was measured with the Zarit scale (completed by the caregiver). Composed of 22 questions on the physical, emotional and financial load felt. Total score /88.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subjects who were included in the EYE-TAR (MA) study, and who completed this study.

  • Subject accompanied by the caregiver already present during participation in the EYE-TAR (MA) study.

  • Written informed consent signed by patient and family caregiver.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace Hospital Monaco Monaco 98000

Sponsors and Collaborators

  • Association de Recherche Bibliographique pour les Neurosciences
  • Centre Hospitalier Princesse Grace

Investigators

  • Principal Investigator: Sandrine LOUCHART DE LA CHAPELLE, MD-PhD, Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Association de Recherche Bibliographique pour les Neurosciences
ClinicalTrials.gov Identifier:
NCT05254873
Other Study ID Numbers:
  • EYE-TAR(MA)-FU
First Posted:
Feb 24, 2022
Last Update Posted:
May 18, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Association de Recherche Bibliographique pour les Neurosciences
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2022